D/E 6.24 — most levered decile in Healthcare (≈95th pctile)
P/E27.1xB
P/E 27.1 — near the Healthcare median (≈60th pctile)
PEG2.11C
PEG 2.11 — expensive relative to growth rate
Forward price target — the 1-year figure is the analyst consensus where the stock is covered; the 5- and 10-year figures compound our earnings estimate from there. The DCF below is a separate cross-check on intrinsic value (what it's worth today), not another target.
Quality-growth score · 58.1
Quality0.76
Growth0.78
Value0.33
Why this score
Raising its dividend
Entry · Margin of safety
52-week rangeNear 52-week high
2% off the 12-month high
vs DCF fair value59% aboveest. fair value ~$244
What the price assumes: free cash flow compounding at ~16% a year for the next decade — vs the ~5% a year our model projects from current growth and analyst estimates.
Quality signals · context only
Gross profitability27% · Bgross profit ÷ total assets (Novy-Marx)
ROIC13.2% · B+return on invested capital — not score-weighted
Why now
Drug Manufacturers - General · market cap $210.3b. Trading near 52-week high of $398.00 — momentum setup, limited technical margin of safety. 29 sell-side analysts rate this a Buy with a mean 1-yr target of $357.03 (implying -8% upside).
Moat
Net margin 21% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 85% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 110% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
D/E 6.24 is elevated — limits strategic flexibility and raises refinancing exposure if rates stay higher for longer. Trading within 2% of the 52-week high — limited technical margin of safety; a momentum reversal would test conviction. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Horizon
1-3 yr $357.03 (29-analyst consensus) — fundamentals + valuation re-rating. 5 yr $522.73 at ~6% CAGR — compounding case rests on the competitive position widening. 10 yr $775.44 if current growth sustains into durable earnings power.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
AMGN vs the Top Picks average
Pillar
AMGN
Book avg
Diff
Quality
0.76
0.83
-0.07
Growth
0.78
0.91
-0.13
Value
0.33
0.75
-0.42
Averaged across the 30 names in today's Top Picks (mean score 81.8). A name can beat these averages and still be absent from the book — it also applies concentration limits.
Score history · AMGN
Trend
+1.0 over 34 daily scores
From 57.1 (Jun 22) → 58.1 (now)
One point per daily model run. The range autoscales, so a flat-looking line can still hide 1–2 point moves — read the From → To values for the actual range.
Position sizing · AMGN
$
%
%
Shares to buy
5
Position size
$1,949
3.9% of portfolio
Stop price
$292.29
25% below $389.71
$ at risk if stopped
$487.14
budget $500.00 · 1% of portfolio
Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.
Amgen Inc. (AMGN): score, valuation & FAQ
Amgen Inc. (AMGN) is a Drug Manufacturers - General company that scores 58.1 out of 100 on the Bull Rankings quality-growth model — a middling reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
Its strongest graded signals are FCF (B+), while D/E (D) rate weaker. On valuation, AMGN sits about 59% above our discounted-cash-flow fair value — the current price implies roughly 16% annual free-cash-flow growth over the next decade.
Is AMGN a good stock to buy?
Bull Rankings scores AMGN 58.1 out of 100 on its quality-growth model, which is a middling reading. That is driven by FCF (B+). A score is a quantitative screen of Amgen Inc.'s fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does AMGN score 58.1 on Bull Rankings?
The quality-growth score blends three pillars — quality (returns on capital, margins, leverage, earnings quality), growth (revenue and earnings expansion), and value (valuation versus sector peers). AMGN earns its highest marks on FCF (B+), and is held back by D/E (D). Each pillar is graded against sector-aware thresholds, then combined into the single 0–100 score.
Is AMGN overvalued or undervalued?
Based on $389.71, AMGN sits about 59% above our discounted-cash-flow fair value — the current price implies roughly 16% annual free-cash-flow growth over the next decade. It trades at a 27.1x× P/E (graded B). Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.
What are the main risks of investing in AMGN?
D/E 6.24 is elevated — limits strategic flexibility and raises refinancing exposure if rates stay higher for longer. Trading within 2% of the 52-week high — limited technical margin of safety; a momentum reversal would test conviction. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Bull Rankings is an automated fundamentals screen for research and education. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a licensed financial adviser.